drug · antibody

BKEMV

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 20 investigational indications.

targets

Complement C5

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BKEMV

trade names

Bekemv, Epysqli, Soliris

generic

ECULIZUMAB-AEEB

MOA

12.1 Mechanism of Action Eculizumab-aeeb, the active ingredient in BKEMV, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab products inhibit terminal complement-mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS. The precise mechanism by which eculizumab exerts its therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction.

indication

1 INDICATIONS AND USAGE BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) BKEMV is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (aHUS) BKEMV is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). 1.3 Generalized Myasthenia Gravis (gMG) BKEMV is indicated for treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

BKEMV

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 20 investigational indications.

targets

Complement C5

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BKEMV

trade names

Bekemv, Epysqli, Soliris

generic

ECULIZUMAB-AEEB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

BKEMV

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

BKEMV

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)